In a Nutshell
GHK-Cu splits in two. Topically it is a mainstream cosmetic ingredient with limited but genuine evidence; as an injection it is unapproved, and FDA has identified no human data supporting it.
GHK-Cu — a copper-binding tripeptide — is the one substance on this hub where the route of administration changes the entire question, and almost nothing written about it makes that distinction.
Topically, GHK-Cu is a mainstream cosmetic ingredient. Copper peptides have been used in skincare for decades, appear in widely sold products, and are studied for effects on skin appearance and wound healing. That is a separate topical-product evidence and regulatory question.
It is also one of the most popular peptides in the wider peptide market, used for skin (collagen support and skin quality) and for hair. Sometimes it is used alone, and often as part of blends marketed as "GLOW" (GHK-Cu with BPC-157 and TB-500) or "KLOW" (the same with KPV). Those blends are usually sold for injection, which is the route where GHK-Cu's regulatory position is weakest, as the next paragraphs explain. Each of the other components has its own evidence and regulatory status — see BPC-157, TB-500 and KPV.
By injection, it is something else — and FDA's record separates the two explicitly.
All GHK-Cu nominations were withdrawn on April 22, 2026. On May 5, 2026 one nominator clarified that it had intended to withdraw only the injectable-route nomination, and FDA consequently returned "GHK-Cu (except for injectable routes of administration)" to Category 1 1. Category 1 means the substance remains under evaluation under FDA's interim policy — not approval, and not final inclusion on the Bulks List.
The injectable route did not come back. FDA states that compounded injectable GHK-Cu "may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities" and that "there are limited data in humans to inform safety-related considerations" 1.
FDA's concern is route-specific. That is unusual and informative — and it means the cosmetic safety record does not transfer to the injectable use.
What GHK-Cu Is
GHK is a three-amino-acid peptide (glycyl-L-histidyl-L-lysine) found naturally in human plasma, which binds copper with high affinity to form GHK-Cu. Plasma levels decline with age, which is the observation most of the anti-aging interest is built on.
Research associates it with wound healing, collagen synthesis, and modulation of genes involved in tissue repair. There is a genuine body of laboratory work behind it — this is not an invented mechanism.
The gap, as elsewhere in this category, is between mechanism and demonstrated clinical outcome — and here, additionally, between one route of administration and another.
Topical vs Injectable
| Topical | Injectable | |
|---|---|---|
| Product category | Commonly marketed as a cosmetic for appearance-related claims; classification depends on intended use — therapeutic or structure/function claims can make a topical product a drug | Unapproved systemic drug use |
| Availability | Widely sold consumer products | Prescription/compounded, or research-grade online |
| FDA compounding status | 503A Category 1 — under evaluation; not approval or final Bulks List inclusion | Injectable-route nomination withdrawn; FDA cites limited human safety data and possible immunogenicity |
| Evidence | Studied for skin appearance and wound healing | Limited human data per FDA |
| Exposure | Primarily local and generally lower than injection, but formulation- and skin-dependent | Direct systemic exposure |
| Main risks | Skin irritation, contact sensitivity | Immunogenicity, sterility, copper exposure, unknown systemic effects |
The practical consequence: a positive experience with a copper peptide serum does not establish the safety of injecting a similarly named active complex. Those are different exposures with different risk profiles, and the marketing for injectable GHK-Cu frequently borrows credibility from the cosmetic use.
What the Evidence Shows
Evidence tier: C for injectable use.
| Claim commonly made | What the evidence supports |
|---|---|
| Improves skin appearance (topical) | Reasonable evidence in the cosmetic literature |
| Supports wound healing | Laboratory and animal work; some clinical interest |
| Stimulates collagen | Supported mechanistically; magnitude in practice less clear |
| Reverses hair loss (injected) | Not established in controlled human trials |
| Systemic anti-aging effects (injected) | Not supported |
The Copper Question
One consideration specific to GHK-Cu that generic peptide discussions miss: it delivers copper.
Systemic copper excess is toxic to the liver and nervous system. But turning that general fact into a GHK-Cu warning requires several things nobody has established: how much elemental copper a marketed injection delivers, whether it stays bound to GHK, how it distributes and clears, and whether repeated dosing changes serum, urinary or hepatic copper at all.
None of that has been studied. Marketed amounts are not standardized, and no adequate human exposure study shows whether any marketed regimen alters copper status. So copper toxicity here is an unquantified theoretical concern, not a documented adverse effect of injectable GHK-Cu — and, to be clear, FDA's own stated concern for the injectable route is limited human safety data and possible immunogenicity, not copper accumulation.
People with Wilson's disease or another diagnosed copper-handling disorder should not use injectable GHK-Cu without specialist review. Beyond that, the current evidence does not support a GHK-Cu-specific copper-toxicity symptom checklist, or routine copper testing in otherwise healthy users.
Safety and What Is Unknown
- Human safety data for injection: limited, per FDA 1
- Copper exposure — theoretical and unquantified; see above
- Immunogenicity: FDA's stated concern regarding aggregation and peptide-related impurities
- Long-term effects and interactions: unstudied
- Wilson's disease or other copper-metabolism disorders: avoid
- Pregnancy and breastfeeding: no data; not appropriate
- Product risk: most injectable GHK-Cu in circulation is research-grade — see peptide sourcing and quality
Red Flags — Seek Care Now
- Fever, spreading redness, swelling or pus at an injection site
- Difficulty breathing, facial or throat swelling, widespread hives — call 911
On Dosing
This page does not provide dosing protocols. No human dose-finding study supports one for injectable use.
What You Can Do About It
If skin quality or hair thinning brought you here, both have assessment pathways and treatments with real evidence. Hair loss in particular has multiple distinct causes — androgenetic, telogen effluvium, thyroid-related, iron deficiency, autoimmune — with different treatments, and getting the diagnosis right determines whether anything works. In midlife, hormonal change drives both skin and hair changes; see hair thinning and dry skin.
Get Started with JumpstartMD
JumpstartMD was founded in 2007 by Stanford-trained physicians. Our programs are built around labs, hormones and body composition, delivered by licensed clinicians you see face-to-face — in person at 14 California locations or online across California — beginning with 60-biomarker lab screening and InBody® body composition scanning. Thyroid function, iron status and hormone levels are all part of that panel, and all are common drivers of skin and hair changes. InBody scans are done in clinic; online members can book one at any of the 14 locations.
Can you get GHK-Cu on prescription?
Injectable GHK-Cu is not FDA-approved, and FDA has flagged concerns specific to injectable routes. Topical GHK-Cu is sold as a cosmetic, which is a different regulatory category with no premarket approval and no requirement to demonstrate efficacy.
If the symptom or goal that led you here has not been evaluated, our clinicians can assess the relevant causes and evidence-based options — that assessment does not assume another peptide is the answer. Peptide care is offered through a paid membership, subject to clinical evaluation. Contact JumpstartMD for membership details and pricing.
Clinician-guided peptide therapy may be considered after an individualized clinical evaluation. Certain therapies may use compounded medications, which are not FDA-approved, and evidence, risks and expected outcomes vary by treatment. See peptide therapy.
Book FREE Consultation
Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.
Share your details and a JumpstartMD team member will reach out when we open.
Related Articles
- Hair Thinning in Menopause — the treatable causes worth identifying
- Dry Skin in Menopause
- Are Peptides Legal in the US?
- How to Tell If a Peptide Is Legitimate
Frequently Asked Questions
What is GHK-Cu used for?
Topically it is a long-standing cosmetic ingredient used for skin appearance, marketed for collagen support and skin texture. By injection it is marketed for tissue repair, hair and systemic anti-aging effects — uses that are not FDA-approved and are not established in controlled human trials.
Is GHK-Cu safe?
Topical use as a cosmetic ingredient has a long consumer history. Injectable use is a different question: FDA states there are limited human data to inform safety considerations and flags immunogenicity risk specifically for injectable routes. The copper content is also worth considering with repeated injection.
Is injectable GHK-Cu FDA approved?
No. The position differs by route: non-injectable GHK-Cu is currently in 503A Category 1 (under evaluation, not approval), while the injectable-route nomination was withdrawn and carries FDA's stated concerns about limited human data and immunogenicity.
Does GHK-Cu regrow hair?
There is no controlled human trial evidence that injected GHK-Cu regrows hair. Hair loss has several distinct causes with different treatments, and getting the diagnosis right matters more than the product.
Can GHK-Cu cause copper toxicity?
There is no evidence that it does at typically marketed amounts, and no long-term human data in which such an effect would have been detected. Copper homeostasis is tightly regulated and excess copper has real toxicity, so anyone with a copper-metabolism disorder such as Wilson's disease should avoid it. It is a fair question to ask any provider offering injections.
Is topical GHK-Cu the same as injectable?
The products may contain the same named active complex, but formulation, concentration, purity, route and resulting exposure are not equivalent. Topical application produces minimal systemic exposure and is regulated as a cosmetic. Injection is systemic, is an unapproved drug use, and carries FDA-flagged concerns specific to that route. A good experience with a serum says nothing about injection safety.
References
- U.S. Food and Drug Administration, "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks." [Online]. Available: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks [Accessed: Jul. 25, 2026]. ↩
- L. Pickart, "The human tri-peptide GHK and tissue remodeling," Journal of Biomaterials Science, Polymer Edition, vol. 19, no. 8, pp. 969-88, 2008, [Online]. Available: https://doi.org/10.1163/156856208784909435. PMID: 18644225. [Accessed: Jul. 25, 2026]. ↩
- R. Teschke, A. Eickhoff, "Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights," International Journal of Molecular Sciences, vol. 25, no. 9, Apr. 2024, [Online]. Available: https://doi.org/10.3390/ijms25094753. PMID: 38731973. [Accessed: Jul. 25, 2026]. ↩
- M. Dakkak, K. M. Forde, H. Lanney, "Hair Loss: Diagnosis and Treatment," American Family Physician, vol. 110, no. 3, pp. 243-250, Sep. 2024. PMID: 39283847. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/39283847/ [Accessed: Oct. 5, 2026]. ↩